Autres langues RepliCel Life Sciences Inc. Toronto S.E.

Actions

RP

CA76027P4006

Marché Fermé - Toronto S.E. Autres places de cotation 17:00:00 16/04/2024			Varia. 5j.	Varia. 1 janv.
0,055 ^CAD	-.--%		-.--%	-15,38 %

2023	RepliCel Life Sciences Inc. annonce ses résultats pour le troisième trimestre et les neuf mois se terminant le 30 septembre 2023	CI
2023	RepliCel Life Sciences Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Canadian Investment Regulatory Organization Trading Halt - RP	08/05
RepliCel Life Sciences : Announces Secured Loan Agreement	18/04
RepliCel Life Sciences Inc. Announces Secured Loan Agreement	18/04
RepliCel Life Sciences : announces a Letter of Intent for Asset Purchase Agreement - Form 6-K	20/03
RepliCel Life Sciences : Letter of Intention (Asset Purchase)	18/03
Canadian Investment Regulatory Organization Trading Halt - RP	15/03
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	30/11
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	28/11
RepliCel Life Sciences : Arbitration decision	16/11
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	24/10/23
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/10/23
RepliCel Life Sciences : AGM 2023 Zoom Link and Materials	22/09/23
Replicel Life Sciences Inc. Announces That Peter Lowry Will Not Be Standing for Re-Election as A Director	30/08/23
RepliCel Life Sciences : Notice of Meeting and Record Date - Form 6-K	17/08/23
RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors	17/08/23
RepliCel Life Sciences Inc. Announces Chief Financial Officer Changes	17/08/23
REPLICEL LIFE SCIENCES : STATEMENT OF EXECUTIVE COMPENSATION - Form 6-K	10/08/23
RepliCel Life Sciences : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	31/05/23
RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	30/05/23
RepliCel Life Sciences : Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options - Form 6-K	18/05/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues RepliCel Life Sciences Inc. Toronto S.E.

Actions

RP

CA76027P4006

Autres langues

Filtres